Digital technologies hold great promise and have the ability to change healthcare and drug
development by changing the way we collect, process, and visualize health data. The …

Introduction Buprenorphine medication assisted treatment (B-MAT) adherence for opioid
use disorder (OUD) is suboptimal. reSET-O, an FDA-cleared prescription digital therapeutic …

Background: Social distancing guidelines for COVID-19 have caused a rapid transition to
telephone and video technologies for delivering treatment for substance use disorders …

Rationale The reconceptualization of substance use disorders (SUD) as a chronic
phenomenon calls for a paradigm shift in service provision, particularly by way of long-term …

The estimated number of Substance Users (SU) globally has currently reached a very high
number and is still increasing. This aspect necessitates appropriate interventions for …

Mental health disorders—including depression, anxiety, trauma-related, and psychotic
conditions—are pervasive and impairing, representing considerable challenges for both …

In 2015, we provided an overview of the use of digital technologies in clinical trials, both as a
methodological tool and as a mechanism to deliver interventions. At that time, there was …

Introduction Treatment retention and adherence are used as outcomes in numerous
randomized clinical trials and observational studies conducted in the addiction field …

Background The COVID-19 pandemic significantly impacted the conduct of clinical trials
through delay, interruption or cancellation. Decentralised methods in clinical trials could …

Although significant advances have been made in the field to date, gender-based issues for
women remain a neglected area in much of substance abuse research. In the current study …